My Green Doctor
MAY 3, 2025
A 2010 research study found that treating two patients per bottle instead of one would decrease plastic waste by approximately 12.69 hospital upwards of $240,000 over 5 years. hospital could save $240,000 per year.” hospital upwards of $240,000 over 5 years. hospital could save $240,000 per year.” 3 “Each U.S.
FDA Law
MAY 30, 2024
Kirschenbaum — Last week, the United States Court of Appeals for the District of Columbia ruled that Section 340B of the Public Health Service Act does not prohibit pharmaceutical manufacturers from imposing conditions on the distribution of discounted drugs to covered entities in the program. In United Therapeutics Corporation v.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
My Green Doctor
MAY 3, 2025
A 2010 research study found that treating two patients per bottle instead of one would decrease plastic waste by approximately 12.69 hospital upwards of $240,000 over 5 years. hospital could save $240,000 per year.” hospital upwards of $240,000 over 5 years. hospital could save $240,000 per year.” 3 “Each U.S.
FDA Law
NOVEMBER 1, 2023
Regulating LDTs: A Long and Winding Road In what might sound to some like protesting too much, the PR invokes FDA’s longstanding assertion that IVDs “manufactured” by laboratories are medical devices and that clinical laboratories that develop tests are acting as manufacturers.
FDA Law
SEPTEMBER 29, 2021
The 340B program, authorized under Section 340B of the Public Health Services Act and administered by HRSA, imposes a ceiling price on pharmaceutical manufacturer sales to “covered entities,” which are certain health clinics that receive federal funding and certain types of safety net hospitals to provide them drugs at lower prices.
Expert insights. Personalized for you.
52 
Let's personalize your content